

Specialty Certificate Examination (SCE) in Medical Oncology 2022 Selected Examination Metrics

The 2022 SCE in Medical Oncology was sat in September 2022 by 209 candidates of whom 69 were self-declared UK trainees. From 2022 'OTH' self-declared UK trainees are excluded from UK trainees' cohort. Candidates who did not declare their training details and the OTH group are reported as 'Other' (140).


Pass Mark

The 2022 Medical Oncology examination was equated using 2019 UK trainees' performance, excluding OTH group, in line with all the other SCEs. The standards of the examination were reviewed in November 2022 and the pass score is maintained to 371. All future examinations will use 371 as the passing score until the standards are reviewed by the SCE Medical Oncology Examination Board.

For the 2022 SCE Medical Oncology examination the pass mark was set at **371 (57.1% or 113/198)**.

UK trainees' performance


In 2022 ST5 UK trainees had the highest sitting number (22) and a pass rate of 95.5%. (21/22) The pass rate for all UK trainees was 75.4% (52/69) and 60.3% (126/209) for all candidates.



The numbers at the top of the bars are the number of trainees sitting.


Topic performance

In 2022 UK trainees had their highest percentage of correct answers in Prostate cancer (76.8%) and their lowest in Leukaemia (17.4%). There are very few questions in these two topics.



Data labels on the chart represent the number of questions per topic

In 2022 Other candidates had their highest percentage of correct answers in Cervical cancer (78.3%) and their lowest in Leukaemia (19.3%). There are very few questions in these two topics.



Data labels on the chart represent the number of questions per topic

MRCP(UK) Research unit
March 2023